Hemoglobin A1c Measurements over Nearly Two Decades: Sustaining Comparable Values Throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study

Overview

Journal Clin Chem

Publisher Oxford University Press

Specialty Biochemistry

Date 2005 Feb 3

PMID 15684277

Citations 63

Authors

Michael Steffes

Patricia Cleary

David Goldstein

Randie Little

Hsiao-Mei Wiedmeyer

Curt Rohlfing

Jack England

Jean Bucksa

Maren Nowicki

Affiliations

Soon will be listed here.

Abstract

Background: Clinical trials require assays that provide consistent results during the course of a study. The hemoglobin A1c (HbA1c) assay, a measure of chronic glycemia, is critical to the study of diabetes control and complications.

Methods: The Diabetes Control and Complications Trial (DCCT) and its follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC), required 20 years of consistent HbA1c results, measured by three different ion-exchange HPLC procedures. To maintain and document consistent HbA1c results measured in the DCCT and EDIC Central Biochemistry Laboratory, a backup laboratory used frozen hemolysates as long-term calibrators and a HPLC method with a single lot of Bio-Rex 70 resin.

Results: Over 20 years, long-term quality-control values have remained constant. Four studies of nondiabetic ranges produced nearly identical values [mean (SD), 5.1 (0.5)%, 4.9 (0.3)%, 5.0 (0.4)%, and 5.0 (0.3)%].

Conclusion: The overall consistency of the HbA1c assays during the 20-year course of the DCCT and EDIC has been critical in establishing the benefits of intensive therapy and in understanding the relationship between long-term glycemia and the development and progression of the complications of diabetes.

Citing Articles

Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use.

Sacks D, Kirkman M, Little R Diabetes Care. 2024; 47(7):1104-1110.

PMID: 38552140 PMC: 11208753. DOI: 10.2337/dci23-0040.

Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.

Sacks D, Arnold M, Bakris G, Bruns D, Horvath A, Lernmark A Diabetes Care. 2023; 46(10):e151-e199.

PMID: 37471273 PMC: 10516260. DOI: 10.2337/dci23-0036.

Case Report: Abnormally Low Glycosylated Hemoglobin A1c Caused by Clinically Silent Rare β-Thalassemia in a Tujia Chinese Woman.

Gao W, Jin Y, Wang M, Huang Y, Tang H Front Endocrinol (Lausanne). 2022; 13:878680.

PMID: 35600576 PMC: 9114733. DOI: 10.3389/fendo.2022.878680.

Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study.

Gubitosi-Klug R, Braffett B, Bebu I, Johnson M, Farrell K, Kenny D Diabetes Care. 2022; 45(3):659-665.

PMID: 35076697 PMC: 8918229. DOI: 10.2337/dc21-0629.

Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.

Boyko E, Zelnick L, Braffett B, Pop-Busui R, Cowie C, Lorenzi G Diabetes Care. 2022; 45(2):357-364.

PMID: 35007329 PMC: 8914413. DOI: 10.2337/dc21-1816.

References

. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group. Clin Chem. 1987; 33(12):2267-71. View

. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1995; 122(8):561-8. DOI: 10.7326/0003-4819-122-8-199504150-00001. View

. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003; 290(16):2159-67. PMC: 2622725. DOI: 10.1001/jama.290.16.2159. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care. 1997; 20 Suppl 1:S1-70. View

. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View

LITTLE R, Rohlfing C, Wiedmeyer H, Myers G, Sacks D, Goldstein D . The national glycohemoglobin standardization program: a five-year progress report. Clin Chem. 2001; 47(11):1985-92. View

. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287(19):2563-9. PMC: 2622728. DOI: 10.1001/jama.287.19.2563. View

Cull C, Manley S, Stratton I, Neil H, ROSS I, Holman R . Approach to maintaining comparability of biochemical data during long-term clinical trials. Clin Chem. 1997; 43(10):1913-8. View

10.

. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999; 22(1):99-111. PMC: 2745938. DOI: 10.2337/diacare.22.1.99. View

11.

Kobold U, JEPPSSON J, Dulffer T, Finke A, Hoelzel W, Miedema K . Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem. 1997; 43(10):1944-51. View

12.

Krishnamurti U, Steffes M . Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem. 2001; 47(7):1157-65. View

13.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

14.

. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes. 1986; 35(5):530-45. View

15.

. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995; 75(14):894-903. DOI: 10.1016/s0002-9149(99)80683-3. View

16.

. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995; 113(1):36-51. DOI: 10.1001/archopht.1995.01100010038019. View

17.

Shrout P, Fleiss J . Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86(2):420-8. DOI: 10.1037//0033-2909.86.2.420. View

18.

Nathan D, Lachin J, Cleary P, Orchard T, Brillon D, Backlund J . Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003; 348(23):2294-303. PMC: 2701300. DOI: 10.1056/NEJMoa022314. View

19.

. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995; 44(8):968-83. View

20.

Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View